

COVID-19 Correlates of Protection Analysis  
Report  
mock Study

USG COVID-19 Response Biostatistics Team

May 14, 2021



# Contents

<b>1</b>	<b>CoP: Correlates of Vaccine Efficacy</b>	<b>9</b>
<b>2</b>	<b>CoP: Controlled Vaccine Efficacy</b>	<b>11</b>
<b>3</b>	<b>Stochastic Interventional Risk and Vaccine Efficacy Effects</b>	<b>13</b>
3.1	Figures with estimates and confidence intervals for Day 57 . . . .	13
3.2	Figures with estimates and confidence intervals for Day 29 . . . .	22
<b>4</b>	<b>Mediators of Vaccine Efficacy</b>	<b>31</b>
<b>5</b>	<b>Appendix</b>	<b>33</b>



# List of Tables

4.1	Table of mediation effect estimates for quantitative markers with 95% confidence intervals. Direct VE = VE comparing vaccine vs. placebo with marker set to distribution in placebo. Indirect VE = VE in vaccinated comparing observed marker vs. hypothetical marker under placebo. Prop. mediated = fraction of total risk reduction from vaccine attributed to antibody response. . . . .	31
4.2	Table of mediation effect estimates for tertile markers with 95% confidence intervals. Direct VE = VE comparing vaccine vs. placebo with marker set to distribution in placebo. Indirect VE = VE in vaccinated comparing observed marker vs. hypothetical marker under placebo. Prop. mediated = fraction of total risk reduction from vaccine attributed to antibody response. . . . .	32



## List of Figures

MOCK

MOCK



## Chapter 1

# CoP: Correlates of Vaccine Efficacy

TO FILL IN

MOCK

## Chapter 2

# CoP: Controlled Vaccine Efficacy

TO FILL IN

MOCK

MOCK


## Chapter 3

# Stochastic Interventional Risk and Vaccine Efficacy Effects

We estimate the counterfactual mean of symptomatic COVID-19 infection under posited shifts in the measured activity levels of each of 4 *candidate* mechanistic correlates of protection (mCoP) biomarkers. By shifting the *standardized* biomarker activity levels by standard unit shifts along the grid  $\{-1, -0.5, 0, 0.5, 1\}$ , we can assess the degree to which vaccines that modulate mCoP biomarker activity to these levels could mitigate symptomatic COVID-19 infection in terms of counterfactual stochastic interventional risk and vaccine efficacy (VE).

### 3.1 Figures with estimates and confidence intervals for Day 57


### 3.1.1 Stochastic interventional risk: spike protein binding antibody




Mean counterfactual COVID-19 infection risk across standardized shifts in spike protein binding antibody levels, summarized by projection of causal dose-response curve onto a linear working model.

3.1. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 57

3.1.2 Stochastic interventional VE: spike protein binding antibody




### 3.1.3 Stochastic interventional risk: RBD binding antibody






3.1. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 57

3.1.4 Stochastic interventional VE: RBD binding antibody




Stochastic interventional vaccine efficacy v. COVID-19 infection across standardized shifts in RBD binding antibody levels, summarized by projection of causal dose-response curve on a linear working model.

### 3.1.5 Stochastic interventional risk: pseudo-neutralizing antibody (ID50)



3.1. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 5719


3.1.6 Stochastic interventional VE: pseudo-neutralizing antibody (ID50)



Stochastic interventional vaccine efficacy v. COVID-19 infection across standardized shifts in pseudo-neutralizing antibody (ID50) levels, summarized by projection of causal dose-response curve on a linear working model.

### 3.1.7 Stochastic interventional risk: pseudo-neutralizing antibody (ID80)


Estimated counterfactual risk of symptomatic COVID-19 infection at Day 57  
working MSM summary: ( $\hat{\beta}_{\text{TMLE}} = -0.0025$ ,  $p\text{-value} = 0.0814$ )



Mean counterfactual COVID-19 infection risk across standardized shifts in pseudo-neutralizing antibody (ID80) levels, summarized by projection of causal dose-response curve onto a linear working model.


3.1. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 5721

3.1.8 Stochastic interventional VE: pseudo-neutralizing antibody (ID80)




## 3.2 Figures with estimates and confidence intervals for Day 29

### 3.2.1 Stochastic interventional risk: spike protein binding antibody




3.2. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 2923

3.2.2 Stochastic interventional VE: spike protein binding antibody




### 3.2.3 Stochastic interventional risk: RBD binding antibody





3.2. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 2925


3.2.4 Stochastic interventional VE: RBD binding antibody



Stochastic interventional vaccine efficacy v. COVID-19 infection across standardized shifts in RBD binding antibody levels, summarized by projection of causal dose-response curve on a linear working model.

### 3.2.5 Stochastic interventional risk: pseudo-neutralizing antibody (ID50)


Estimated counterfactual risk of symptomatic COVID-19 infection at Day 29  
 working MSM summary: ( $\hat{\beta}_{\text{TMLE}} = 0.0017$ ,  $p\text{-value} = 0.5332$ )



Mean counterfactual COVID-19 infection risk across standardized shifts in pseudo-neutralizing antibody (ID50) levels, summarized by projection of causal dose-response curve onto a linear working model.

3.2. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 2927


3.2.6 Stochastic interventional VE: pseudo-neutralizing antibody (ID50)



Stochastic interventional vaccine efficacy v. COVID-19 infection across standardized shifts in pseudo-neutralizing antibody (ID50) levels, summarized by projection of causal dose-response curve on a linear working model.

### 3.2.7 Stochastic interventional risk: pseudo-neutralizing antibody (ID80)


Estimated counterfactual risk of symptomatic COVID-19 infection at Day 29  
working MSM summary: ( $\hat{\beta}_{\text{TMLE}} = -5\text{e-}04$ , p-value = 0. 7622)



Mean counterfactual COVID-19 infection risk across standardized shifts in pseudo-neutralizing antibody (ID80) levels, summarized by projection of causal dose-response curve onto a linear working model.

3.2. FIGURES WITH ESTIMATES AND CONFIDENCE INTERVALS FOR DAY 2929

3.2.8 Stochastic interventional VE: pseudo-neutralizing antibody (ID80)



MOCK

## Chapter 4

# Mediators of Vaccine Efficacy

Table 4.1: Table of mediation effect estimates for quantitative markers with 95% confidence intervals.

Direct VE = VE comparing vaccine vs. placebo with marker set to distribution in placebo.

Indirect VE = VE in vaccinated comparing observed marker vs. hypothetical marker under placebo.

Prop. mediated = fraction of total risk reduction from vaccine attributed to antibody response.

Time	Assay	Direct VE	Indirect VE	Prop. mediated
Day 57	Binding Antibody to Spike	NA	NA	NA
Day 57	Binding Antibody to RBD	NA	NA	NA
Day 57	PsV Neutralization 50% Titer	NA	NA	NA
Day 57	PsV Neutralization 80% Titer	NA	NA	NA
Day 29	Binding Antibody to Spike	NA	NA	NA
Day 29	Binding Antibody to RBD	NA	NA	NA
Day 29	PsV Neutralization 50% Titer	0.205 (0.142, 0.262)	0.856 (0.823, 0.883)	0.894 (0.927, 0.861)
Day 29	PsV Neutralization 80% Titer	0.823 (0.729, 0.884)	0.352 (-0.032, 0.593)	0.200 (0.408, -0.007)

<sup>a</sup> NA denotes insufficient overlap in antibody response between vaccinated and control participants.

Table 4.2: Table of mediation effect estimates for tertile markers with 95% confidence intervals.

Direct VE = VE comparing vaccine vs. placebo with marker set to distribution in placebo.

Indirect VE = VE in vaccinated comparing observed marker vs. hypothetical marker under placebo.

Prop. mediated = fraction of total risk reduction from vaccine attributed to antibody response.

Time	Assay	Direct VE	Indirect VE	Prop. mediated
Day 57	Binding Antibody to Spike	0.865 (0.723, 0.934)	0.157 (-0.577, 0.549)	0.078 (0.369, -0.212)
Day 57	Binding Antibody to RBD	0.777 (0.677, 0.846)	0.487 (0.305, 0.622)	0.308 (0.450, 0.166)
Day 57	PsV Neutralization 50% Titer	0.736 (0.643, 0.805)	0.568 (0.485, 0.637)	0.386 (0.480, 0.293)
Day 57	PsV Neutralization 80% Titer	0.742 (0.646, 0.812)	0.557 (0.460, 0.637)	0.375 (0.479, 0.272)
Day 29	Binding Antibody to Spike	0.890 (0.784, 0.944)	-0.047 (-0.927, 0.431)	-0.021 (0.260, -0.303)
Day 29	Binding Antibody to RBD	0.940 (0.701, 0.988)	-0.909 (-7.917, 0.591)	-0.299 (0.407, -1.004)
Day 29	PsV Neutralization 50% Titer	0.917 (0.700, 0.977)	-0.388 (-3.702, 0.590)	-0.151 (0.409, -0.712)
Day 29	PsV Neutralization 80% Titer	0.905 (0.809, 0.953)	-0.208 (-1.262, 0.355)	-0.087 (0.201, -0.376)



## Chapter 5

# Appendix

- This report was built from the [CoVPN/correlates\\_reporting](https://github.com/CoVPN/correlates_reporting/commit/a275c3b5a03588f181f4d43fe77d68d7ab25d646) repository with commit hash a275c3b5a03588f181f4d43fe77d68d7ab25d646. A diff of the changes introduced by that commit may be viewed at [https://github.com/CoVPN/correlates\\_reporting/commit/a275c3b5a03588f181f4d43fe77d68d7ab25d646](https://github.com/CoVPN/correlates_reporting/commit/a275c3b5a03588f181f4d43fe77d68d7ab25d646)
- The sha256 hash sum of the raw input file, “COVID\_VEtrial\_practicedata\_primarystage1.csv”:  
2353971c2e14399ede55ef6ba0d4e624626433dc15ec507c2482bb886210019a
- The sha256 hash sum of the processed file, “practice\_data.csv”:  
6250066f886245b78f7aa29fec615ba5d10118448f298c39ec2b601b2a5049f